Home » PDUFA Provisions Could Harm FDA and Industry, Expert Says
PDUFA Provisions Could Harm FDA and Industry, Expert Says
August 29, 2007
Some of the provisions in the FDA Revitalization Act, S. 1082 and H.R. 2900, would be ineffective, could cripple the FDA and would put unnecessary burdens on pharmaceutical companies, Center for Medicine in the Public Interest President Peter Pitts said. “Political battles are trumping public health,” he added.